Akums Drugs and Pharmaceuticals Limited — Updates, 14-05-2026: Press Release

Akums posted robust Q4 & FY26 results: Revenue up 9.7% to ₹1,158 Cr (Q4) & 5.9% to ₹4,359 Cr (FY26), with Adj PAT surging 135% (Q4) & 27.3% (FY26). CDMO business drove growth. Global expansion continued; API segment faces pricing pressure. Board declared a ₹3/share dividend.